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Etravirine with 2 NRTIs: an effective switch option for ARV
simplification and side effect management
Smith, G; Brunetta, J; Loutfy, M; Crouzat, F; Hedgecock, M; Merkley, B; Chang, B; Tilley, D; Kovacs, C and Fletcher, D
Maple Leaf Medical Clinic, Toronto, Canada.
Etravirine (ETV) has been approved for use in treatment-experienced patients based on results of the Duet clinical trials [1]. Less
experience exists with ETV in earlier stages of treatment. ETV has a favorable genetic barrier, lipid profile, and little associated
CNS toxicity.These characteristics make ETV attractive as a switch strategy for simplification and/or management of side effects.
A retrospective chart review was conducted at a large urban HIV clinic in Toronto. All patients who were switched to ETV plus
2 nucleosides and whose viral load (VL) was B200 copies/ml at the time of switch were included. Maintenance of viral
suppression, CD4 and lipid changes at 24 weeks and reason for switch to ETV are reported. Seventy-three patients (67 male)
were identified. Mean age was 46910 and mean duration of HIV infection was 11.797.4 years. Switches were from
efavirenz29, atazanavir23, lopinavir16, other5. Duration of prior regimen was long; median 195 weeks. CNS and GI
intolerance were the most common reasons for switches. At the time of analysis, 63 patients had reached week 24. Three
patients had discontinued ETV prior to week 24, 3 LTF/U, 4 had B24 weeks follow-up. 92% (67/73) maintained VL suppression
(ITT); failures were 6 patients who stopped/lost-to-follow-up prior to week 24. On treatment, CD4 increased and lipid decreased
changes as seen below. All patients who switched due to CNS side effects had subjective improvement.
Switch to ETV plus 2 nucleosides maintained viral suppression, improved lipid profiles and improved side effect profile in this
selected group of patients. 48 week f/u will be presented.
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Baseline Change from baseline to week 24 (OT, n63) P value
CD4 (cells/mm
3) 6329269 499137 B0.01
Total cholesterol (mmol/L) 4.7691.11 0.5790.77 B0.01
HDL (mmol/L) 1.2090.36 0.0590.21 0.06
LDL (mmol/L) 2.7191086 0.4090.73 B0.01
Triglycerides (mmol/L) 2.0691.86 0.5591.76 0.02
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